Commission approves first oral GLP-1 agonist for obesity and overweight patients in the EU

17 July 2026 by Wendy WINN (DG SANTE, European Commission)

The oral 25 mg pill has been cleared for treating adults who are considered clinically obese with a Body Mass Index (BMI) of 30 or more, as well as adults who are considered overweight with a BMI of 27 or over. This pill formulation of the weight-loss therapy Wegovy was recommended for approval...

Register to the Health Policy Platform

See full publication (Platform members only)